Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
Make way for MiniMed! Medtronic's diabetes division has filed the necessary paperwork to go public. The company hopes to be traded on Nasdaq under the symbol MMED.
The Pennsylvania-based drug distributor announced it would be buying OneOncology, a physician-led specialty service group in which it already owned a minority stake. The company said the acquisition will complement its "pharmaceutical-centric strategy."
Paxton says the “woke” EHR giant is intentionally making it harder for patients and families to access historical medical data, violating state law. Epic denies the allegation.
Mark Cuban's startup Cost Plus Drugs and insurer Humana are said to be working on a deal that would allow Medicare Advantage patients to buy drugs directly from manufacturers. The terms of the agreement—which Forbes reports is in its early stages—are still unknown.
Over 97% of all counties in the U.S. see high or very high levels of consolidation in Medicare Advantage markets, with UnitedHealthcare and Humana owning the most plans nationwide.
Former Steward Health Care CEO Ralph de la Torre, MD, and other executives are accused in a $1.4 billion legal filing of paying themselves hundreds of millions of dollars in bonuses, despite the health system being insolvent.
In a new report, the New York Times details multiple incidents of the insurance giant using legal threats to silence social media users and news outlets, citing the murder of Brian Thompson and the threat of rising violence as the basis for its claims.
Shareholders of the retail pharmacy giant voted in favor of the terms of the sale to Sycamore Partners for $11.45 a share. The deal is expected to close later this year.
Xealth’s data sharing platform will be used to make use of health information gathered from everyday devices like the Samsung Galaxy Smartwatch, the companies said.
The pharmacy chain said it plans to appeal the ruling. The complaint was brought by a former employee turned whistleblower who alleged that Omnicare had billed the government for millions of unnecessary prescriptions.